{
    "clinical_study": {
        "@rank": "131020", 
        "arm_group": {
            "arm_group_label": "Chloroquin in addition to Gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety by defining the maximum tolerated dose\n      (MTD) of Choloroquine when combined with Gemcitabine, and to evaluate preliminary efficacy\n      of combined systemic Gemcitabine and Chloroquine. In addition, the influence of the\n      treatment on the anti-cancer immunity and the value of GOLPH2 as serum marker for pancreatic\n      cancer will be assessed within a translational objective.\n\n        -  Trial with medicinal product"
        }, 
        "brief_title": "Adjuvant Effect of Chloroquine on Gemcitabine", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically confirmed non-resectable locally advanced or\n             metastatic adenocarcinoma of the pancreas. Assessment is done within 21 days before\n             enrolment.\n\n          -  Age = 18 years\n\n          -  Adequate liver function or kidney function tests, including any of the following:\n             Bilirubin < 2 x ULN, Alanin-Aminotransferase (ALT) < 5 x ULN, Alcaline phosphatase <\n             5 x ULN, Estimated creatinine clearance > 40 ml/min (using the Cockroft formula)\n\n          -  Adequate haematological values: Haemoglobin > 80 g/L, Leukocytes >3.00 g/L,\n             Neutrophils > 1.00 g/L, Platelets > 100 g/L\n\n          -  Written informed consent\n\n          -  Biliary decompression is mandatory before inclusion into the study in case of\n             bilirubin levels > 50 \u00b5mol/L.\n\n          -  Women who are not breastfeeding and are using effective contraception if sexually\n             active, who are not pregnant and agree not to become pregnant during the 12 months\n             thereafter. A negative pregnancy test before inclusion into the trial is required for\n             women of childbearing potential, defined as having not reached the menopause, last\n             menstrual period occurred less than 12 months ago, no surgical sterilization\n             performed, and fallopian tubes and/or uterus have been not surgically removed.\n\n          -  Men who agree not to father a child during participation in the trial or during the\n             12 months thereafter.\n\n        Patient compliance and geographic proximity allow proper staging and follow-up. Patient\n        not eligible for FOLFIRINOX treatment. WHO PS 0-2\n\n        Exclusion criteria:\n\n          -  Life expectancy < 3 months\n\n          -  Severe medical or psychiatric co-morbidity prohibiting the planned treatment or the\n             giving of informed consent\n\n          -  Any prior chemotherapy for pancreatic cancer, including adjuvant chemotherapy.\n\n          -  Any prior radiotherapy or combined radio-chemotherapy for pancreatic cancer if\n             completed less than 12 months prior to study inclusion.\n\n          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of\n             the trial drugs.\n\n          -  Known glucose-6-phosphate dehydrogenase deficiency.\n\n          -  Concurrent use of other experimental drugs, treatment within a clinical trial within\n             30 days prior to trial entry.\n\n          -  Active heart disease defined as congestive heart failure > NYHA class 2\n\n          -  Past or current history (within the last 2 years prior to treatment start) of other\n             malignancies except basal or squamous cell carcinoma of the skin or in situ carcinoma\n             of the cervix\n\n          -  Inability or unwillingness to comply with the study protocol\n\n          -  No understanding of the german language"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777477", 
            "org_study_id": "ONK-USZ-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chloroquin in addition to Gemcitabine", 
                "description": "Addition of Chloroquine to Gemcitabine", 
                "intervention_name": "Chloroquine", 
                "intervention_type": "Drug", 
                "other_name": "Nivaquin"
            }, 
            {
                "arm_group_label": "Chloroquin in addition to Gemcitabine", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine", 
                "Chloroquine diphosphate", 
                "Gemcitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Department of Oncology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Gemcitabine Combined With Chloroquine in Patients With Metastatic or Unresectable Pancreatic Cancer. A Dose Finding Single Center Phase I Study", 
        "overall_contact": {
            "email": "panagiotis.samaras@usz.ch", 
            "last_name": "Panagiotis Samaras, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Department of Oncology", 
            "last_name": "Panagiotis Samaras, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}